DRGDEVCON

Dr Salazar has over 25 years of pharmaceutical research and development experience with significant accomplishments across all phases of development and different therapeutic areas. He has significant knowledge of drug discovery, development, regulatory submissions and organizational leadership. He has made significant contributions to over 40 IND filings and 9 NDAs including Abilify®, Benicar HCT®, Azor®, Tribenzor®, Welchol®, Effient® and Lixiana®. He is currently Chief Science Officer and a Director at EMS, S.A and Vice Presidnet at Brace Pharma Capital. Dr Salazar is also a Director for Tyrogenex, Inc and GeNO LLC. Dr Salazar completed his undergraduate education at Princeton University where he majored in Biology and his Doctor of Pharmaceutical Science from the State University of New York at Buffalo. Dr Salazar is an Adjunct Associate Professor, Department of Pharmaceutics, Univeristy of Florida. He has directed over 100 clinical studies investigating dosage form bioequivalence,..